Ventyx Biosciences, Inc. financial data

Symbol
VTYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
12790 El Camino Real, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.68K % -3.04%
Debt-to-equity 9.87 % +40.2%
Return On Equity -54.9 % -1.22%
Return On Assets -50 % +1.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.7M shares +19.8%
Common Stock, Shares, Outstanding 70.7M shares +19.8%
Entity Public Float 1.3B USD +238%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 70.7M shares +20%
Weighted Average Number of Shares Outstanding, Diluted 70.7M shares +20%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 134M USD -18.1%
General and Administrative Expense 32.2M USD -0.34%
Operating Income (Loss) -166M USD +15.2%
Nonoperating Income (Expense) 13.9M USD -6.37%
Net Income (Loss) Attributable to Parent -153M USD +15.9%
Earnings Per Share, Basic -2.36 USD/shares +25.1%
Earnings Per Share, Diluted -2.36 USD/shares +25.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 61.8M USD +9.11%
Marketable Securities, Current 213M USD -12.8%
Cash, Cash Equivalents, and Short-term Investments 252M USD -29.3%
Assets, Current 289M USD -6.06%
Property, Plant and Equipment, Net 703K USD +2.48%
Operating Lease, Right-of-Use Asset 9.92M USD -16.3%
Other Assets, Noncurrent 96K USD -5.88%
Assets 301M USD -6.4%
Accounts Payable, Current 2.29M USD -75.5%
Employee-related Liabilities, Current 4.41M USD -16.5%
Accrued Liabilities, Current 9.01M USD -45.1%
Liabilities, Current 12.3M USD -53.1%
Operating Lease, Liability, Noncurrent 10M USD -15.4%
Liabilities 22.3M USD -41.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 873K USD
Retained Earnings (Accumulated Deficit) -525M USD -41%
Stockholders' Equity Attributable to Parent 279M USD -1.72%
Liabilities and Equity 301M USD -6.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -47.6M USD -54%
Net Cash Provided by (Used in) Financing Activities 96.2M USD +97.7%
Net Cash Provided by (Used in) Investing Activities 41.8M USD
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 70.7M shares +19.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 90.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.7M USD +8.95%
Deferred Tax Assets, Valuation Allowance 98.1M USD +118%
Deferred Tax Assets, Gross 101M USD +122%
Operating Lease, Liability 11M USD -10.5%
Depreciation 100K USD
Payments to Acquire Property, Plant, and Equipment 175K USD +192%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -151M USD +16.3%
Lessee, Operating Lease, Liability, to be Paid 15.3M USD -14.4%
Property, Plant and Equipment, Gross 1.12M USD +30.7%
Operating Lease, Liability, Current 1.01M USD +111%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.14M USD -17.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.07M USD -5.64%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.31M USD -22.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.2M USD -7.99%
Deferred Tax Assets, Operating Loss Carryforwards 52.8M USD +81%
Unrecognized Tax Benefits 1.87M USD +54.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.27M USD +3%
Operating Lease, Payments 400K USD +300%
Additional Paid in Capital 803M USD +22.3%
Deferred Tax Assets, Net of Valuation Allowance 2.48M USD +685%
Share-based Payment Arrangement, Expense 23.9M USD -12.3%